EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting

  • Christopher Larson

Press/Media

Period2 Apr 2024

Media coverage

5

Media coverage